Hypoxic cell radiosensitizers in the treatment of high grade gliomas: A new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole)

This publication has 28 references indexed in Scilit:

• A comparison of the tumour concentrations obtainable with misonidazole and Ro 03–8799
  The British Journal of Radiology, 1986
• Phase I trial of the hypoxic cell radiosensitizer SR-2508: The results of the five to six week drug schedule
  International Journal of Radiation Oncology*Biology*Physics, 1986
• Chemical sensitizers for hypoxic cells: A decade of experience in clinical radiotherapy
  Radiotherapy and Oncology, 1985
• Results of the phase I trial of the hypoxic cell radiosensitizer SR 2508
  International Journal of Radiation Oncology*Biology*Physics, 1984
• Clinical trials of radiosensitizers: What should we expect?
  International Journal of Radiation Oncology*Biology*Physics, 1984
• The pharmacokinetics of a new radiosensitiser, Ro 03-8799 in humans
  European Journal of Clinical Pharmacology, 1984
• The penetration of misonidazole and desmethylmisonidazole into brain tumours and other central nervous system tissues in man
  The British Journal of Radiology, 1983
• SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use
  International Journal of Radiation Oncology*Biology*Physics, 1981
• Structure-activity Relationships in the Development of Hypoxic Cell Radiosensitizers
  International Journal of Radiation Biology, 1979
• RADIOTHERAPY AND HYPERBARIC OXYGEN IN HEAD AND NECK CANCER
  The Lancet, 1977